Amarin Zelapar "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amarin's orally disintegrating formulation of selegiline, Zelapar, is deemed "approvable" Feb. 7. The NDA, for use of Zelapar as an adjunct to levodopa for symptoms of Parkinson's disease, was accepted for filing by FDA April 6, 200
You may also be interested in...
Somerset Emsam NDA Resubmission Adds Long-Term Indication, Higher Doses
Somerset’s resubmitted NDA for the selegiline patch Emsam seeks an indication for relapse prevention as well as treatment of depression.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.